A Safety and Immunogenicity Phase IC Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device

Trial Profile

A Safety and Immunogenicity Phase IC Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2015

At a glance

  • Drugs ASP 4070 (Primary)
  • Indications Allergic rhinitis
  • Focus Adverse reactions
  • Sponsors Immunomic Therapeutics
  • Most Recent Events

    • 24 Mar 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 07 Aug 2014 Planned End Date changed from 1 Oct 2014 to 1 Nov 2014, as per ClinicalTrials.gov record.
    • 07 Aug 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Nov 2014, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top